  0086-18989305995        sales@mosinterchem.com
You are here: Home / Products-list / Pharmaceutical Chemicals API / Circulatory System Drugs API / Apixaban CAS 503612-47-3 BMS-562247

PRODUCTS DETAILS

Apixaban CAS 503612-47-3 BMS-562247

Model: C25H25N5O4
Place of Origin: Shandong,China (Mainland)
Brand: MOSINTER
Molecular Formula: C25H25N5O4
Molecular Weight: 459.50
Specification: CP/USP/EP
Content: 98%min
Density: 1.421g/cm3
CAS: 503612-47-3
Boiling point: 770.468°C at 760 mmHg

  • 503612-47-3
  • MOSINTER
  • 503612-47-3
Product Description

Payment & Shipping Terms

Supply Capacity

Payment Terms:

T/T, WU

Production Capacity:

500Ton/year

Min. Order:

1 Gram

Packing:

according to the customer's requirements 

Means of Transport:

Ocean, Air, Land

Delivery Date:

7 days

 

Apixaban ( CAS: 503612-47-3 )

 

Item

Index

Molecular Formula

C25H25N5O4

Molecular Weight

459.50

Specification

CP/USP/EP

Content

98%min

 

Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. 

 

Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued. There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for about 24 hours after the last dose (i.e., about two half-lives). A specific antidote is not available.  Although treatment with apixaban does not require routine monitoring of exposure, the Rotachrom® anti-FXa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.

 

Discontinuation

There is increased risk of (mainly ischemic) stroke with discontinuation of apixaban. Discontinuing apixaban in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from apixaban to warfarin in clinical trials in patients with nonvalvular atrial fibrillation within the first 30 days of transition. This resumption of events was probably related to inadequate control of anticoagulation, but induction of a hypercoagulable state by long-term treatment with the NOAC has not been ruled out. If apixaban must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.

 

 

 

 


PRODUCT INQUIRY
If you would like to have a question then get in touch today, we are ready to assist 24/7.
We welcome your cooperation and we will develop with you.
Factory-direct Connectivity Solutions.
High quality, Competitive Price.
Custom-tailored solutions.
Problem-solving approach.

OUR PRODUCT/SERVICE

MOSINTER GROUP was established in 2004. The main office is located in Ningbo, China. The production are located in Zhejiang Province, Jiangsu Province and Shandong Province in China. Specializing in the production and marketing of chemical products, MOSINTER GROUP has excellent production equipment and a high-performing sales team as well as advanced manufacturing technique, comprehensive quality management system and modernized testing methods.

QUICK LINK

CONTACT INFO

  0086-18989305995
 0086-574-88212215
  sales@mosinterchem.com
  YinXianDaDao 1357, Guangbo Center Office 2003, Ningbo, Zhejiang, China
 forwardcy
 0086-18989305995
 0086-18989305995
Copyright  2020 Mosinter Group Limited All rights reserved.